Atlas Trials

Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer

Clinical trial NCT03772353 · UNKNOWN

Trial details

NCT number
NCT03772353
Sponsor
Fudan University
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2019-05-12
Primary completion
2023-06-10
Enrollment
59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.